found that in vivo administration of the rapamycin analog temsirolimus prevented the hyperactivation of the AKT–mTOR pathway in the hearts of mice with cardiomyopathy caused by the LMNA mutation and suppressed the deterioration of cardiac function. Here, AKT1 is linked to cardiomyopathy.